Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on BioCryst Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

BioCryst Pharmaceuticals is a U.S. public bio/pharmaceutical company that discovers drugs for the treatment of infectious diseases, inflammatory diseases and cancer. It plans to raise $45 million in a secondary public offering, as reported in the PharmSource Lead Sheet on March 16, 2017.

Corporate Highlights

  • BioCryst Pharmaceuticals was incorporated in Delaware in 1986
  • Corporate Headquarters: Durham, NC – approximately 15,000 square feet of office and laboratory space
  • Research Facility: Birmingham, AL – approximately 32,000 square feet of office and laboratory space
  • As of January 31, 2017, they had 65 employees
  • Stock Exchange: NASDAQ
  • Stock Symbol: BCRX

Sourcing Opportunities

  • BioCryst Pharmaceuticals plans to use the proceeds for future clinical development of BCX7353, for continued development of its second-generation compounds for HAE and other indications and for the advancement of its other preclinical rare disease programs.
    • BCX7353 – To complete a Phase II study:
      • For treatment of hereditary angioedema attacks
      • Dosage Form: Capsule
      • Nature of API: Chemical – Normal potency
      • Therapeutic Area: Hematology; Immunomodulator
  • Second Generation HAE – To complete preclinical studies:
    • For treatment of hereditary angioedema
    • Dosage Form: Oral
    • Nature of API: Chemical – Normal potency
    • Therapeutic Areas: Cardiology/Vascular
  • The company contracts with contract research organizations (CROs) to conduct ongoing and planned clinical trials.
  • Due to BioCryst Pharmaceuticals’ limited manufacturing experience and a small scale manufacturing facility, they currently rely on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • BioCryst Pharmaceuticals has limited sales, marketing and distribution capabilities.
  • Business Relationships

    • On June 16, 2015, BioCryst Pharmaceuticals and Seqirus UK, a subsidiary of CSL Ltd., entered into a license agreement for Seqirus to acquire worldwide rights, excluding Israel, Japan, Korea and Taiwan, to develop, manufacture, and commercialize RAPVAB for the treatment of influenza. Under the terms of the agreement, BioCryst Pharmaceuticals received an upfront payment of $33.7 million with up to another $12 million based on milestone payments.
    • On February 28, 2007, BioCryst Pharmaceuticals and Shionogi & Co. (Shionogi) entered into an exclusive license agreement where Shionogi will develop and commercialize Peramivir in Japan for the treatment of influenza. In October 2008, Shionogi expanded territory coverage to include Taiwan. BioCryst Pharmaceuticals receives an upfront payment of $14 million and up to $116 million in development and commercial milestone payments.1

    Drug Product Pipeline

    Product Candidate Indication Dosage Form Status Next Anticipated Step
    Second Generation HAE Hereditary Angioedema Oral Preclinical TBA
    BCX4430 Viral Hemorrhagic fever; Ebola; Marburg virus disease Parenteral Phase I TBA
    BCX7353 Hereditary Angioedema Capsule Phase II TBA
    Rapivab (Peramivir) Influenza Parenteral Approved/Marketed TBA

    Finances

    (In $ thousands) 2016 2015
    Revenues
    26,353
    48,257
    R&D Expenditures
    61,008
    72,758
    General & Administrative Expenditures
    11,253
    13,047
    Total Operating Expenses
    74,960
    87,701

    1BioCryst Pharmaceuticals, Inc. 2/27/17 10-K, SEC.gov

    Contact Information

    BioCryst Pharmaceuticals, Inc. Key Officers
    4505 Emperor Blvd., Suite 200 Jon P. Stonehouse, President & CEO
    Durham, NC, 27703 USA Carrie Rivera, Director, QA
    Phone: +1-919-859-1302 Andreas Maetzel, VP, Medical Affairs
    Fax: +1-919-859-1314 William P. Sheridan, SVP & CMO
    Web: www.biocryst.com Elliott Berger, PhD, SVP, Regulatory Affairs

    Related posts:
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Aldeyra Therapeutics, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Zynerba Pharmaceuticals, Inc.
    Follow the Money to Pharmaceutical Opportunities – Spotlight on Clearside Biomedical, Inc.

    Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

    More posts by Scotty Chung-Siu